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a b s t r a c t
Providing information about single virus particles has for a long time been mainly the domain of electron
microscopy. More recently, technologies have been developed—or adapted from other ﬁelds, such as
nanotechnology—to allow for the real-time quantiﬁcation of physical virion particles, while supplying
additional information such as particle diameter concomitantly. These technologies have progressed to
the stage of commercialization increasing the speed of viral titer measurements from hours to minutes,
thus providing a signiﬁcant advantage for many aspects of virology research and biotechnology
applications. Additional advantages lie in the broad spectrum of virus species that may be measured
and the possibility to determine the ratio of infectious to total particles. A series of disadvantages remain
associated with these technologies, such as a low speciﬁcity for viral particles. In this review we will
discuss these technologies by comparing four systems for real-time single virus particle analysis and
quantiﬁcation.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Measuring virus concentrations
From basic research on emerging viral diseases to clinical applica-
tions of viral gene therapy vectors—it is often vital to quantify viral
amounts accurately. As a consequence awide spectrum of methods is
in use for the determination of virus concentrations. They may be
grouped broadly into four categories: (a) determining levels of
infectivity, (b) measuring the presence or function of viral proteins,
(c) detecting the presence of viral or marker nucleic acid within the
viral genome and (d) counting physical viral particles, whether
labeled or unmarked (see Table 1).
Methods to determine infection levels include measurements
of cytopathic effects such as plaque forming and 50% tissue culture
infectious dose (TCID50) assays but also ﬂow cytometric measure-
ments of cellular transduction after infection with viral particles
carrying reporter genes such as green ﬂuorescent protein
(Metzner et al., 2008; Papanikolaou et al., 2013). While hemagglu-
tination assays directly measure the propensity of viral proteins to
crosslink susceptible cell types, serological methodologies also
measure the presence of viral antigens, albeit indirectly, by
determining antibody conversion. Generally, the use of antibody
technology has had a great impact on virus quantiﬁcation, since
high speciﬁcity and sensitivity are achieved, i.e. in enzyme-linked
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immunosorbent assay (ELISA) formats. However, stringency of ELISA
approaches for virus quantiﬁcation can be considered to be low, as the
measured viral element is not necessarily linked to a virus particle (see
Table 1). Even if considerably faster than cell-culture based methods, it
will take hours to complete the assay. The advent of molecular
techniques, especially polymerase chain reaction (PCR), has also left
its mark on the quantiﬁcation of viral particles. Both RNA and DNA
levels can be measured using quantitative PCR approaches. Absolute
quantiﬁcation (i.e. copy numbers or numbers of particles) can be
obtained from relative raw data by using standard dilutions of vector
DNA or RNA. PCR may also be used to quantify protein levels. In
product-enhanced reverse transcriptase (PERT) assays, production of
DNA from viral RNA by the reverse transcriptase being present in the
retroviral sample is quantiﬁed and used in turn to estimate virus
particle concentration (Metzner et al., 2013). PCR and protein detection
methods offer advantages in terms of the time needed to get results
when compared to cell-culture based methods. Indeed, no culturing is
necessary, which constitutes a signiﬁcant advantage since culturing
may not be possible in all cases. Nevertheless, stringency for this
techniques can also be considered to be low, as the measured viral
element—in this case the nucleic acid—is not necessarily part of avirion
(infectious or otherwise), and calculations may signiﬁcantly over-
estimate the number of particles present (see Table 1 and Fig. 1)
Counting virion particles
The analysis of single virus particles has long been the remit of
electron microscopy. Recently, technical progress in the ﬁeld of
microscopy as well as the adaptation of applications originally devel-
oped for use in nanotechnology crossed over to uses in virology and
made the quantitative analysis of single viral particles as physical
entities more feasible. Technologies include atomic force microscopy
(AFM) (Ohnesorge et al., 1997), laser light scattering applications such
as multiple-angle laser light scattering (MALLS) (Bousse et al., 2013;
Wei et al., 2007) or nanoparticle tracking analysis (NTA) (Papanikolaou
et al., 2013; Filipe et al., 2010; Kramberger et al., 2012; Anderson et al.,
2011; Du et al., 2010), tunable resistive pulse sensing (TRPS, a method
based on the Coulter principle) (Vogel et al., 2011; Farkas et al., 2013;
Rybakova et al., 2013), and ﬂow cytometry (FC) variants (Brussaard
et al., 2000; Ferris et al., 2011; Stepp et al., 2011, 2010; Kemp et al.,
2012). Other methods that appear to fall into this category are not
discussed in any greater detail, such as viral quantitative capillary
electrophoresis (vqCE) (Mironov et al., 2011), since correlates of
particle counts (such as nucleic acid amounts) are used for calculation
of virus titers, similar to qPCR, rather than the presence of virion
particles. However, vqCE is of special interest, since it is able to
distinguish between the intact virus fraction and free DNA (Mironov et
al., 2011)—an interesting aspect when trying to evaluate PCR based
quantiﬁcation data. This review will concentrate on technologies that
show themost promise in the ﬁeld and have as such progressed to the
stage of commercial availability, namely ﬁeld-ﬂow fractionation (FFF)-
MALLS, NTA, “ﬂow virometry” using a VirusCounter (VC) device and
TRPS (see Table 2).
FFF-MALLS
FFF-MALLS equipment offered by Wyatt Technology (http://www.
wyatt.com) combines a separation step using variants of FFF with a
detection step using MALLS. FFF is a liquid chromatography technique
where sample separation occurs in a laminar ﬂow channel with no
columnmedia to interact with the sample. Particles are eluted in order
of increasing size, and separation of the sample is rapid and gentle.
The eluted particles will be detected by MALLS, which provides
simultaneous detection of light scattered from several angles, provid-
ing additional information compared to other laser light scattering
approaches. By measuring the intensity and angular dependency of
the scattered laser light, it is possible to deduce the radius of the
particles i.e. determine size distributions (Chuan et al., 2008; Pease et
al., 2009) and subsequently calculate the number of particles per
volume (Bousse et al., 2013; Wei et al., 2007). FFF-MALLS data was
compared tomeasurements of infectivity levels and qPCR for Inﬂuenza
preparations. For samples from a range of sources, following vaccine
production procedures, the highest values determined were observed
for qPCR measurements followed by results from FFF-MALLS and
measuring the correlate of infectivity (Bousse et al., 2013; Wei et al.,
2007) (see also Table 3). As measuring infectivity is the most stringent
method, these results could be expected (see also Tables 1 and 3).
Similar to the comparison of different methods for measuring
Table 1
Methods of virus quantiﬁcation. The table summarizes some of the most common methods used for the quantiﬁcation of virus. TCID50 tissue culture infectious dose 50;
ELISA enzyme-linked immunosorbent assay; PERT—product-enhanced reverse transcriptase assay; SRID—single radial immunodiffusion assay; (RT-)qPCR—(reverse
transcriptase) quantitative polymerase chain reaction; NTA—nanoparticle tracking analysis; VC—VirusCounter; TRPS—tunable resistive pulse sensing; FFF-MALLS—ﬁeld-
ﬂow fractionation multiple-angle laser light scattering; AFM—atomic force microscopy.
Category Type Time to result Stringency Comment
Viral quantiﬁcation methods
Infectivity Plaque assay Days–week(s) High Virus must replicate in culture
Marker transduction Days–week(s) High
TCID50 Days–week(s) High
Protein ELISA Hours–day(s) Low Measured viral element not necessarily linked to viral particle
Hemagglutination Hours–day(s) Low
PERT Hours–day(s) Low
Neuraminidase Hours–day(s) Low
Immunoblotting Hours–day(s) Low
SRID Hours–day(s) Low
Nucleic acid qPCR Hours Low
RT-qPCR Hours Low
Particle Electron microscopy Hours Medium Inherent low speciﬁcity for virus
Flow cytometry Minutes–hour(s) Medium
NTA Minutes–hour(s) Medium
Flow (VC) Minutes–hour(s) Medium
TRPS Minutes–hour(s) Medium
FFF-MALLS Minutes–hour(s) Medium
AFM Minutes–hour(s) Medium
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lentiviral counts, qPCR indicated higher concentrations than the
particle based approach (compare Fig. 1). We believe that this is the
result of different requirements for measurement; in qPCR only the
nucleic acid needs to be present, while for FFF-MALS (or TRPS) more
parts of the virus need to come together. The combination of
separation and puriﬁcation steps prior to detection is a promising
concept for single particle quantiﬁcation approaches, since sample
purity is crucial for a precise measurement. Currently, the effort in
terms of technical expertise and equipment is higher compared to the
other techniques. However, this is mostly due to two different
technologies having to be implemented separately.
Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) has been developed by
NanoSight Ltd. (www.nanosight.com), which was recently
acquired by Malvern Instruments Ltd. This real-time nanoparticle
visualization is based on a laser-illuminated microscope technique.
A laser beam is passed through an optical prism, and the result-
ing refraction is used to compress the beam into an intense
illumination region, where nanoparticles can be visualized. The
Brownian motion of nanoparticles, i.e. virus particles, in liquid are
detected by either a charge-coupled device (CCD) camera, or more
recently a complementary metal–oxide–semiconductor (CMOS)
sensor based system which transforms the optical information
into electronic data. Modern CMOS sensors can process more
frames per second and are thus well suited for the application:
the video captured with this camera showing the movement of
individual particles is subsequently analyzed using NTA software.
It automatically calculates the distance each particle moves, and by
knowing temperature and viscosity of the solvent, the particle
diameter can be calculated using a variation of the Stokes–Einstein
equation. Depending on the refractive index (Ri) of the nanopar-
ticles, lower size limits for this detection method range between
10 nm for particles with high Ri such as colloidal gold, and 30 nm
for lower Ri such as particles with biological origin. The upper size
limit is determined by Brownian motion, as movement becomes
too limited to track accurately, when the particles reach approxi-
mately 1 mm in diameter. As the NTA approach measures single
particles simultaneously, a sufﬁcient number of particles can be
analyzed in 60 s according to manufacturer's claims; an important
factor to make this possible is that samples contain between 107
and 109 particles per mL. As quantiﬁcation is usually needed for
samples with unknown concentration, the dilution steps needed
to reach this (quite small) gap may result in signiﬁcant longer time
needed for sample preparation. Therefore, the time taken per
measurement may vary between 5 min and 1 h (Filipe et al., 2010).
Several groups tried to investigate the usefulness of the NanoSight
device for viral particle quantiﬁcation. Mironov et al. (2011)
published that this technique provides a good indication of
particles per volume when measuring Vaccinia virus samples,
although it quickly reaches its technical limits when host cell
debris or other background particles are present, indicating the
need for efﬁcient virus sample puriﬁcation strategies. NanoSight's
performance can also be extended by labelling virus particles with
ﬂuorophores to discriminate them from host cell debris or identify
speciﬁc virus species (for more information see http://www.
nanosight.com/technology/ﬂuorescence-capability#6). Although
particle-based methods are unable to distinguish between infec-
tious and non-infectious particles, labelling (i.e. for viral proteins
mediating cell entry) may be an option to increase the stringency
of the method. Anderson et al. (2011) correlated NanoSight's
results with plaque assay and quantitative PCR for quantifying
bacteriophages and concluded that it is less precise, but provides
results more quickly (within 5 min). The drawbacks they faced
were that NTA only worked when phage samples were suspended
in clear medium. They also commented on the high price of the
equipment and the relatively small concentration range for which
accurate results could be generated. Nevertheless, they stated that
the NTA based method, once optimized, will likely be reproducible
with accuracy comparable to plaque assays only signiﬁcantly
faster. When adenoviral preparations were analyzed using a
cytopathic effect based cell culture assay and NTA, results varied
by two to three logs. In all cases NanoSight measurement yielded
the higher value (Kramberger et al., 2012) (see also Table 3). The
same group used hemagglutinin (HA) titration and NTA for
quantiﬁcation of Inﬂuenza preparations (Kramberger et al.,
2012). No particle numbers were, however, derived from HA
values since appropriate standards for allowing an absolute
quantiﬁcation were missing. Thus, no direct comparison of infec-
tious to total particles was possible in this case. When a lentiviral
vector pseudotyped with vesicular stomatitis virus G (VSV-G)
protein was analyzed using ﬂow cytometry after reporter gene
Fig. 1. Comparison of strategies for measuring viral concentrations. (A) Levels of
stringency in virus titer measurement. The type of parameter measured inﬂuences
the stringency and thus the level of titers measured: measuring infectivity will
always give lower titers than measuring particle numbers, protein or nucleic acid
amounts based measurements. In this case, infectious titers (measured by ﬂow
cytometry after reporter gene transduction), total particle number (measured by
TRPS), reverse transcriptase levels (measured by PERT assay) and viral RNA
containing a GFP reporter (measured by RT qPCR) were determined in triplicate
for 8 different preparations of lentiviral particles, derived from the stable producing
cell line STAR-A-HV (ECACC no. 04072115). Viral preparations were concentrated by
ultracentrifugation (2 h, 56,000g, 4 1C in a Beckmann XL70 ultracentrifuge using a
SW32ti rotor). Concentrations for each preparation are shown together with the
respective means and standard error of the mean (SEM). TRPS—tunable resistive
pulse sensing; PERT—product-enhanced reverse transcriptase assay; qPCR—quan-
titative polymerase chain reaction. (B) Average vs. distribution. While the two
distributions depicted are clearly distinct, they yield the same average (indicated by
the vertical dotted line). When using ensemble methods, subpopulations may be
hidden, indicating the importance of single particle analysis.
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transduction and NanoSight, only 0.1% of nascent virions was
found to be infective (Papanikolaou et al., 2013) (see also
Table 3), providing important information on the quality of the
vector preparation. In addition, NTA total particle titers of ﬂuor-
escently tagged non-infectious HIV-1 virus-like particles were
shown to be in good agreement with measurements based on
electron microscopy and p24 ELISA (1.241011; 1.141011 and
1.301011, respectively) (Gutierrez-Granados et al., 2013; Cervera
et al., 2013). Recently, NTA has been used to compare size and
amounts of human cytomegalovirus (HCMV) virions and dense
bodies (DB), a type of non-infectious particles produced by HCMV
(Cayatte et al., 2013).
Virus Counter
Virocyt (http://www.virocyt.com) has developed a ﬂow
cytometer-like device (VirusCounter; VC) suitable for virus quan-
tiﬁcation in liquid samples. Recently, a modiﬁed version of the
device has been presented, better suited for industrial applications
(for more info see http://virocyt.com/news/new-rapid-virus-coun
ter-system-introduced-at-world-vaccine-congress/). VC uses two
separate ﬂuorescent dyes to stain virus samples: one speciﬁc for
proteins, the other for nucleic acids. Both, a certain size of virus
(425 nm) and a certain length of viral genome (49000 nt/bp)
are necessary to guarantee a sufﬁcient level of staining for
Table 2
Commercially available techniques for single-particle quantitiative analysis of virus particles. FFF—ﬁeld-ﬂow fractionation; NTA—nanoparticle tracking analysis; VC—
VirusCounter; TRPS—tunable resistive pulse sensing.
FFF-MALLS NTA Flow (VC) TRPS
Single particle quantiﬁcation techniques
Hardware Eclipse/dawn NanoSight VirusCounter qViroX, qNano
Developer/
producer
Wyatt Malvern Virocyt Izon
www.wyatt.com www.nanosight.com www.virocyt.com www.izon.com
Detection
principle
Light scattering Light scattering Fluorescent in-ﬂow
detection
Coulter principle
Label-free Label-free Dual-label Label-free
Time/sample Depending on separation 5 min to 1 h 30 min (staining)
o5 min detection
o10 min
Size range (in
nm)a
450 30–1000 425 (49000 nt) 60–2000
Concentration
rangea
410Eþ06b 10Eþ07–10Eþ09 10Eþ05–10Eþ09 10Eþ05–10Eþ12
Pros Separation step included,
size measurement
Additional ﬂuorescence measurement enhancing speciﬁcityc Easy handling, quick
results
Small, inexpensive hardware,
charge and size measurements
Cons Elaborate set-up, little
testing on virus
Narrow concentration range No additional
parameters measured
Little peer-reviewed literature
for use on virus
Costs For information on pricing please contact manufacturer
References Bousse et al., 2013; Wei et
al., 2007; Chuan et al., 2008;
Pease et al., 2009
Papanikolaou et al., 2013; Kramberger et al., 2012; Anderson et
al., 2011; Du et al., 2010; Gutierrez-Granados et al., 2013;
Cervera et al., 2013; Cayatte et al., 2013
Ferris et al., 2011;
Stepp et al., 2011, 2010;
Kemp et al., 2012
Vogel et al., 2011; Farkas et al.,
2013; Rybakova et al., 2013;
Brussaard et al., 2000
a According to manufacturer.
b According to Bousse et al. (2013).
c According to http://www.nanosight.com/technology/ﬂuorescence-capability#6.
Table 3
Measuring the ratio of total to infectious particles. T:I ratio of total to infectious particles; FFF—ﬁeld-ﬂow fractionation; NTA—nanoparticle tracking analysis; VC—
VirusCounter; TRPS—tunable resistive pulse sensing.
Technique Virus Descriptiona Infectivity by Infectious titer Total particles Ratio T:I Reference
Determining the infectivity index
FFF-MALS Inﬂuenza V/e/80–120/13.5 Plaque assay 2.00Eþ07 2.00Eþ08 10 Bousse et al. (2013)
Inﬂuenza V/e/80–120/13.5 TCID50 2.51Eþ08 7.94Eþ09 31.63 Wei et al. (2007)
NTA Adenovirus I/n/90/35–36 TCID50 2.00Eþ09 1.79Eþ11 89.50 Kramberger et al. (2012)
Adenovirus I/n/90/35–36 Plaque assay 4.00Eþ10 4.19Eþ11 10.48 Du et al. (2010)
Bacteriophage I/n/50–110(head)/33–
244
Plaque assay n.a. n.a. 1.5–5b Anderson et al. (2011)
Lentivirus (VSV-G) VI/e/80–100/9.75 Reporter gene transduction 7.25Eþ08 7.40Eþ11 1,02Eþ03 Papanikolaou et al. (2013)
Flow (VC) Adenovirus I/n/90/35–36 TCID50 4.70Eþ06 1.10Eþ09 234.04 Stepp et al. (2010)
Baculovirus I/e/20260/80–180 Plaque assay 5.80Eþ06 1.40Eþ08 24.14 Ferris et al. (2011)
Coronavirus IV/e/120/27–32 TCID50 1.60Eþ06 2.50Eþ08 156.25 Stepp et al. (2010)
Cytomegalovirus I/e/150–200/200 TCID50 2.10Eþ08 3.30Eþ10 157.14 Stepp et al. (2010)
Denguevirus IV/e/50/10–11 TCID50 8.90Eþ07 1.90Eþ09 21.35 Stepp et al. (2010)
Herpes Simplex Virus I/e/150–200/152 TCID50 2.10Eþ08 3.70Eþ10 176.19 Stepp et al. (2010)
Inﬂuenza V/e/80–120/13.5 TCID50 3.60Eþ06 1.60Eþ10 4.44Eþ03 Stepp et al. (2011)
Parainﬂuenza V/e/150/15 TCID50 1.00Eþ08 2.90Eþ08 2.90 Stepp et al. (2010)
Respiratory Syncytial virus V/e/150/15 TCID50 3.20Eþ07 4.60Eþ10 1.44Eþ03 Stepp et al. (2010)
Rubella IV/e/65–70/8.7–11.8 TCID50 1.00Eþ07 5.90Eþ10 5.90Eþ03 Stepp et al. (2010)
TRPS Lentivirus (amphoMLV) VI/e/80–100/9.75 Reporter gene transduction 1.08Eþ06 7.99Eþ10 7.42Eþ04 unpublished data
a Description data is given in the following format: baltimore class/naked (n) or enveloped (e)/diameter (in nm)/genome size (in kb), Source: http://viralzone.expasy.org/.
b Estimated from correlation data.
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detection. Only events positive in both channels are counted as
viral particles. The non-speciﬁc staining process eliminates the
need for target-speciﬁc reagents such as ﬂuorescence-labelled
antibodies required for conventional ﬂow-cytometry methods
and is therefore more cost-effective (Ferris et al., 2011; Schulze-
Horsel et al., 2008). Staining for protein/nucleic acid also reduces
signal from inorganic contamination, i.e. nano-sized salt precipi-
tates in buffer solutions. VC is the only method mentioned in this
review which relies on labelling for measurement. This may
introduce non-speciﬁcally stained signals. Generally, labelling
procedures may change sample properties (such as diameter or
zeta potential) and will increase the time to measurement. How-
ever, only ﬂuorescence is measured and staining the virus particles
requires 30 min incubation only and subsequent analysis can be
accomplished in around 10 min per sample according to the
manufacturer's documentation. In trials run by the authors mea-
surement times were generally shorter (5 min). The viral particle
concentration is calculated from the number of particles generat-
ing positive events in both channels and the sample ﬂow rate; the
range for reliable measurements is 5n105 to 1n109 virus particles
per mL. As for FFF-MALS, NTA or TRPS, there are currently only a
few research groups testing and/or evaluating the VC. Stepp et al.
(2010) determined TCID50, concentration by transmission electron
microscopy (TEM) and compared the results to measurements
from the VC for a broad range of virus species from Adeno—via
Herpes Simplex to parainﬂuenzavirus (see also Table 3). They
could show good agreement between the different measurement
methods. Ferris et al. (2011) generated recombinant baculovirus
samples which were tested in house by plaque assay and subse-
quently sent to collaborators which performed plaque assays or
measurements with VC. After de-blinding, they were able to show
that VC provides statistically signiﬁcant results—determined by
linear regression analysis of log-transformed average results and
Pearson correlation analysis—to plaque assays, with a considerable
advantage in terms of time needed to get results. VC was also used
to control viral titers in a baculovirus-based expression system
(Kemp et al., 2012). When Inﬂuenza A/H1N1 samples were
investigated for virus concentration using TCID50, EM and VC,
the titers were 3.6106, 1.61010 and 1.61010 particles per mL
respectively (Stepp et al., 2011). Also in this case a relatively big
gap between infectious and total particle numbers is observed.
Generally, two reasons contribute to the difference between
infectious and total virus counts: (i) cells produce particles
resembling virus which are not infectious, either as a consequence
of viral infection (i.e. Hepatitis B) or as a consequence of cellular
physiological processes (i.e. exosomes); (ii) artefacts of preparation
contribute to the gap: formation of aggregates will increase total
particle count, while loss of infectivity may occur during prepara-
tion procedures. For example, the lentiviral particles we have used
in our TRPS study are particularly prone to the latter (see Fig. 1).
Ultracentrifugation negatively affects the molecules responsible
for viral entry.
Tunable resistive pulse sensing
TRPS, originally termed scanning ion occlusion sensing (SIOS) is
the technology behind the qNano and qViroX devices marketed by
Izon Ltd. (www.izon.com), which utilizes a stretchable membrane
to achieve size-adjustable nanopores for counting and measuring
the size of particles passing through the pore (Vogel et al., 2011). In
addition, measurement of zeta-potential is possible (Kozak et al.,
2012). This parameter describes the electrokinetic potential in a
colloidal system. It provides information similar to charge data,
and can help to predict attachment behavior or stability of a viral
preparation (Zhang et al., 2008; Arjmandi et al., 2012). The
adjustable pore is the central part of this technique which offers
the possibility to measure particles in a range from 60 nm to 2 mm,
thus excluding some of the smaller virus families. The pore is
located in the elastic polyurethane center of a cruciform support
which is placed within the ﬂuid cell of the qViroX instrument. By
stretching the membrane mechanically, the pore is size-adjusted
according to individual needs. The ﬂuid cell is characterized by
Ag/AgCl electrodes localized in the upper and lower compart-
ments of the cell, which are used to apply a potential difference
across the pore. By building an electrolytic ﬂuid bridge, the current
across the pore can be measured by qViroX's software. Samples are
applied to the upper compartment of the ﬂuid cell and as particles
pass through the pore, so-called blockade events in the ionic
current are created leading to resistive pulses, which have a linear
relationship to the particle volume. Fundamentally, this is an
application of the Coulter principle. Particles can pass through
the pore due to their charge. For weakly charged or neutral
particles there is the possibility to apply pressure in order to
increase the ﬂow of particles through the pore, which is also a
helpful tool to measure samples of low concentration. qViroX is
calibrated with carboxylated polystyrene particles in deﬁned sizes
and known concentrations. Samples are analyzed under the same
conditions. Size distributions are calculated using a comparison
between the blockade magnitude distributions of the calibration
particles and unknown samples (Vogel et al., 2011). TRPS is
reported to be able to measure particle size and size distribution
of nanoparticles with good accuracy, precision and sensitivity in
several different nanoparticles including silica nanoparticles, DNA-
coated nanoparticles, adenovirus and liposomes (Yang et al., 2012).
One group tested qViroX for size measurements (but not for
concentration measurements) of Adenovirus samples and drew
the conclusion that size measurements by TRPS were in good
agreement to electron microscopy results (Vogel et al., 2011).
Vogel et al. (2011) described the nanopores and standard particles
they used in detail, analyzed them by EM and described repro-
ducible size measurements for standard particles over a range of
membrane stretches. In our group TRPS was used to quantify
lentiviral particles derived from a stable lentiviral producer cells
line called STAR-A-HV (Ikeda et al., 2003). Our results showed that
measurements of particle concentration (7.991010 particles per
mL) were considerably higher than infectious titers (1.08106
particles per mL) but lower that results from PERT (1.161013
particles per mL) or RT-qPCR protocols (2.331012 particles per
mL) (see also Fig. 1 and Table 3), indicating that only 0.001% of
nascent virions are infectious. This represents a 100fold decrease
compared to results achieved with VSV-G pseudotyped lenti-
viruses and NTA measurement (Papanikolaou et al., 2013), most
likely due to the less stable amphotropic Murine Leukemia virus
(MLV) Env present in STAR-A-HV-derived viral particles. Indeed,
when we used sucrose cushions for concentrating the preparation,
infectious titers improved on average ten-fold (unpublished data).
However, a comparison is difﬁcult since different methods for
particle quantiﬁcation were used. In addition to the work done in
our group, TRPS has been used to quantify Rotavirus particles. The
results from this study also suggest a gross overestimation of
Rotavirus particles due to empty capsids and cellular debris
(Farkas et al., 2013). This indicates that as with the other methods,
great care has to be given to sample preparation, as the nanopore
will get clogged when too crude samples are used. In our hands,
TRPS membranes tended to block more easily than VC ﬂuidics—an
issue that may be rectiﬁed by changing the properties of the
membranes surface, i.e. by coating with low adsorption materials.
Bacteriophage tail-like particles have also been quantiﬁed by TRPS
(Rybakova et al., 2013), indicating that the form of particles does
not affect measurement. TRPS can also be used to analyze the
interaction between two elements or particles in bio-sensing
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applications (http://www.izon.com/applications/bio-diagnostics/
gold-nanoparticles-for-biosensing/), by following the size distribu-
tion. This may represent a possibility for speciﬁc detection, similar
to the use of immuno-gold staining in electron microscopy.
Antibody-functionalized nanoparticles could be associated with
viral samples. Subsequently, the increase of particle size would
demonstrate the speciﬁc interaction between nanoparticle and
virus particle (http://www.izon.com/capabilities/particle-interac
tion-monitoring/). The qViroX has the smallest bench footprint
of all the devices mentioned and is easily transportable.
Discussion: the pros and cons of physical virion quantiﬁcation
Importantly, the quantitative single particle assays rely on
parameters devoid of biological connotations (with the exception
of protein/nucleic acid labelling for the VC) for the quantiﬁcation
of virus particles. In contrast, the established virus quantiﬁcation
methods are based on infectivity, protein or nucleic acid levels.
However, the same information is ultimately presented: the
number of particles per volume. The process of inferring this
information gives rise to inherent differences when comparing
results with other types of information (see Fig. 1A). For example,
infectious titers, whether measured by plaque assays or by level of
cellular transduction with a marker protein (as is the case in
Fig. 1A) will always give lower concentration than methods based
on the presence of nucleic acid, protein or particles (see also
Table 3). This is explained by the level of stringency associated
with the measurement parameters; while for protein or nucleic
acid based methods the presence of said factors alone is enough, in
measurement of infectivity all (or most) elements of the virus
need to be in place correctly to allow infectivity. Measuring the
presence of particles somehow lies in between: factors making up
the virus need to be in the correct shape or form of aggregation.
However, functionality is not required. This effect is even exag-
gerated in Fig. 1A, since a very crude ultracentrifugation protocol
was used, largely destroying the infection capability of lentiviral
particles pseudotyped with MLV amphotropic envelope protein. In
addition, PERT assay, RT-qPCR and TRPS were used to quantify
eight different preparations in triplicates (shown in Fig. 1A). In this
case the stringency of TRPS seems to be ten-fold higher than that
of PERT or qPCR. Similar results were obtained when Inﬂuenza
samples were investigated using TCID50, EM, and VC for virus
quantiﬁcation (Stepp et al., 2011). Also for Inﬂuenza, comparing
FFF-MALS data to infectious titer correlates and qPCR conﬁrms
this, as does analysis of adenovirus samples with the NTA method
(Kramberger et al., 2012) (see Table 3 for an overview). However,
these differences in the measurement principles make it possible
to investigate important questions in virology. While cells may
produce a vast quantity of physical viral particles, only a portion of
these will be fully infectious (Ibiricu et al., 2013; Meckes and Raab-
Traub 2011). Non-infectious particles produced upon viral infec-
tion can contribute to viral spread in numerous ways, i.e. by
providing an immune decoy. Comparing such different types of
vesicles, i.e. according to size using the described technologies is
possible and has been described for the dense bodies produced by
HCMV infected cells (Cayatte et al., 2013). In gene therapy, the
percentage of infectious particles in a given viral vector stock will
signiﬁcantly inﬂuence the efﬁcacy of gene transfer and thus is a
main parameter for vector stock quality control. All methods
presented have the capability to measure total virus particles,
thus allowing the determination of total to infectious particle
ratios (ratio T:I; see Table 3). Another open question concerns the
relationship between viral particle production (especially in the
case of enveloped viruses) and the production of other lipid
vesicles of a similar size range, such as exosomes (Meckes and
Raab-Traub 2011; Raposo and Stoorvogel 2013), which may con-
tribute to particle counts but not to infectivity levels as they are
common contaminants of viral preparations (Cantin et al., 2008).
Exosomes have recently garnered a greater degree of interest, not
only for their functions in cell-to-cell communication, but also for
their potential use as a source of biomarkers (Properzi et al., 2013)
or as gene delivery/therapy vectors (El-Andaloussi et al., 2012).
Generally, the interplay of virus particles and exosomes is an
interesting topic (Meckes and Raab-Traub 2011; Wurdinger et al.,
2012). Single-particle analysis techniques including NTA (El-
Andaloussi et al., 2012; Twu et al., 2013) and TRPS (de Vrij et al.,
2013; Ng et al., 2013) have also been used for the characterization
of exosomes. Most single-particle analysis techniques will also
allow additional parameters to be measured, such as virus dia-
meter or charge. In this respect, an inherent advantage of single
particle analysis is that distributions of distinct values, rather than
averages, are generated. Averaged data may hide subpopulations
(see Fig. 1B) important for answering research questions, for
example the discrimination of exosomes and viral particles.
In addition, measuring size distributions will help to determine
the aggregation state of particles in solution. This is an important
parameter in several applications, i.e. when assessing the quality
of viral vectors for gene therapy, or vaccine preparations. Aggrega-
tion data has been derived from AFF-MALS data for Inﬂuenza (Wei
et al., 2007) and NTA measurements for lentiviral preparation
(Papanikolaou et al., 2013). TRPS experiments have been used to
investigate aggregation in an adenoviral sample (Vogel et al.,
2011). Depiction of size distribution in histograms allows for an
easy interpretation (Papanikolaou et al., 2013; Vogel et al., 2011).
In addition to size distribution, information from zeta potential
measurements can help, since particles with higher zeta potential
(i.e. 425 mV) will repulse each other more readily, thus increas-
ing monodispersity of preparations. Generally, the “average vs.
distribution” topic resembles the difference between results from
immunoblot analysis and ﬂow cytometry; while the ﬁrst will
provide information about the average presence of a protein of
interest in cells, the latter will provide information about the
distribution over the cells (or viruses) comprising the sample.
An advantage shared by all the methods, is the time it takes for
sample analysis, which is measured in minutes rather than in days
or hours (see Tables 1 and 2). Particle numbers are counted
directly and not inferred from infectivity, protein or nucleic acid
levels. There is no need for culturing of viral particles and
potentially a broad range of viruses can be measured with the
same technology. All methods contribute information to deter-
mine the ratio of total to infectious particles with similar levels of
stringency. However, problems are also shared between the
different techniques. A peer-reviewed literature is still scarce.
Sample preparation—mostly ﬁltration to remove larger particulate
material—is vital, both to ensure that the optimal measurement
conditions determined by the device (i.e. avoiding blocking of
ﬂuidics) are met and to keep contamination levels low. Measure-
ments to determine background noise levels in buffer are also
critical. Measurements using single particle detection are of
moderate stringency and speciﬁcity. FFF-MALS, TRPS and NTA
measure the presence of particles in a speciﬁc size range: they
may be virus particles, exosomes, cellular debris of appropriate
size or inorganic contamination from buffers (indicating once
more the strong inﬂuence of sample preparation on results).
Subsequently, measurements in complex sample matrices, such
as serum, will be difﬁcult. The VC partially addresses this problem
by staining viral particles for both nucleic acid and protein. While
this may distinguish viral particles from cellular debris and
inorganic contamination, it may not sufﬁciently discriminate virus
from exosomes, which carry both protein and RNA. What is
required is a possibility to label virus speciﬁcally, i.e. using
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ﬂuorescent tagged antibodies and then detect this in parallel along
with the usual parameter. This has already been implemented for
NTA and may be most easily implemented for the VC, since
ﬂuorescence detection is already in place. Currently, the potential
for high-throughput measurement is limited, meaning options to
measure several samples in parallel are lacking. However, the most
recent version of the VC includes a 96-well compatible autosam-
pler. Also, a combination of fractionation and detection, as sug-
gested by the FFF-MALS system, may both make handling easier
and allow a better estimation of contamination levels. Generally,
handling requires experience from the operator. In this aspect, the
VC system may prove to be the most robust. Multiple additional
parameters such as size or charge (zeta potential) of particles can
be measured by TRPS (Kozak et al., 2012), FFF-MALS (Wei et al.,
2007) and NTA (Kramberger et al., 2012), but not the VC. This is
interesting when trying to ﬁnd subpopulations in viral prepara-
tion, i.e. for the quality control of viral vector or vaccine produc-
tion, to identify contamination or aggregation events.
Comparing costs for the different systems is somehow difﬁcult.
On the one hand, prices for the devices themselves may vary
considerably, depending on conditions of purchase agreements
and speciﬁc device set-up (e.g. there are three different set-ups
available for NTA, two devices available for VC). On the other hand,
costs of consumables have to be taken into consideration: mainly
the membranes containing the nanopores for TRPS and the
ﬂuorescent labelling cocktail for VC measurements. Contacting
the manufacturers on costs for devices and consumables is,
therefore, indispensable.
However, the ﬁnal question still remains: what method to
choose in order to quantify virus particles? Unfortunately, there is
no clear single answer available—since sufﬁcient comparative data
on the use of the different systems is lacking—except that the
combination with quantitative real-time single particle analysis
methods will likely provide important supportive information, and
ultimately, access to equipment may determine the choice of
technology.
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